Early Access — free while we kick the tires
EdgarHawk

HOWL Werewolf Therapeutics, Inc. Insider Trading

1 filing analyzed · Latest 2025-05-14
Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying

Historically, high-priority insider buys have outperformed the S&P 500 by a median ~2% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 5,751, 2021-2026). Past results don't predict the future. How we measure this ↗

May 2025
2025-05-14
high
536,426 shares
$487,188
@ $0.91
Significance 7/10

RA Capital Management bought 536,426 shares at blended $0.91 across 3 transactions; now holds 6.24M shares (+9.4%).

RA Capital Management, listed as a Director, executed 3 separate purchases totaling 536,426 shares for $487,187.92 at a blended average price of $0.91 on May 12-14, 2025, increasing its position from 5.70M to 6.24M shares. The timing coincides with a 30-day stock price gain of +28.3%, though the stock remains -82.2% from its 52-week high of $5.57 and trades at current price $0.99. The company is unprofitable with net income of $-18,089,000.00 and a market cap of $44,424,909.54, indicating a cash-constrained biotech profile. Across RA Capital's cross-ticker open-market history, 18 prior buys averaged +20.4% return over 30 days (69.23% win rate), suggesting a track record of timely buy decisions, though historical performance does not guarantee outcomes at this particular ticker.

Insiders here also file at

More Chemicals and Allied Products companies

Get alerts for HOWL

Add HOWL to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access